Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Navitoclax Alone or with Ruxolitinib in Myelofibrosis
2017-001398-17Phase 2Unknown
- Sponsor
- AbbVie Inc.
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of navitoclax in myelofibrosis (MF) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Spleen volume reduction ≥35% at week 24. Status: unknown.
02
Drugs
navitoclax
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on 2017-001398-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001398-17.